karsinoma

Karsinoma is a rare type of malignant tumor that originates in epithelial tissues, although it can also arise in a variety of non‑epithelial sites. The disease is distinguished by its unique histopathological features, including the presence of keratinizing squamous cells in a fibrous stroma that is often accompanied by a component of sarcomatous differentiation. Because of this mixed cellular composition, karsinoma is sometimes classified within the spectrum of carcinosarcomas.

The exact cause of karsinoma remains unknown, but risk factors are thought to mirror those of other epithelial cancers, such as chronic inflammation, exposure to carcinogens, and genetic predisposition. In many reported cases the tumor develops in the genital tract, uterus, or soft tissues of the lower extremities, but it can also occur in the orofacial region, the respiratory tract, and the gastrointestinal system.

Clinical presentation depends on the tumor’s location. Patients may report a rapidly enlarging mass, pain, ulceration, or obstruction of organ function. When karsinoma involves the genital tract, bleeding or changes in urinary function are common. Due to its aggressive behavior, metastatic spread, particularly to regional lymph nodes and distant sites, can occur early in the disease course.

Diagnosis is made by imaging studies such as MRI or CT, followed by a core needle biopsy. Histology confirms the carcinoma component and the sarcomatous capsule, with immunohistochemical staining often used to delineate the two components. Molecular profiling may reveal mutations in the TP53 gene, although epidemiologic data are sparse.

Treatment is multimodal. Surgical excision with wide margins is often the first step, and may be followed by radiation therapy and chemotherapy. Platinum‑based regimens combined with taxanes are frequently employed, but the response varies. Given the rarity of karsinoma, randomized trials are lacking, and most management decisions rely on case series and expert consensus. Research efforts are focused on clarifying the tumor’s biology and identifying targeted therapies for the sarcomatous component.

Epidemiologic data are limited; estimates suggest an incidence of fewer than one per 100,000 persons annually worldwide. Because many cases are reported as isolated case studies, overall survival rates are not well defined, but reported survival ranges from 6 months to 3 years depending on stage at diagnosis and treatment modality.